Novartis
Novartis to present cardiovascular data at ESC Congress 2026
Ten abstracts across Novartis's cardiovascular portfolio will highlight Leqvio, abelacimab and Entresto, including late-breaking Phase IV trial results and Lp(a) testing strategies.
Swiss stocks rise; Geberit surges 7.4% on strong half-year results
Swiss market leads Europe as SMI gains 0.5% to 14,387; Roche and Novartis advance on pharma optimism, while insurance stocks lag amid bond-market pressures.
M&G appoints Daiichi Life executive as non-executive director
Hitoshi Yamaguchi joins M&G’s board as part of a strategic partnership with Daiichi Life Group. The appointment strengthens ties between the insurers and takes effect in September 2026.
US stocks mixed pre-market; Moderna surges 100% on cancer therapy data
Moderna jumps 100% in premarket trading after data showed its personalized mRNA cancer vaccine combined with Merck’s Keytruda cut melanoma recurrence. SMI rises 0.36% as Lowe’s cuts guidance, Estee Lauder gains.
Swiss stocks edge up as Roche, Novartis lead; ABB, Amrize weigh
The SMI rose 0.13% to 14,321 points, with healthcare heavyweights Roche and Novartis offsetting losses in ABB and Amrize. Global bond yields surged to multi-year highs, unsettling investors.
US stocks rise as Moderna surges 150% on cancer vaccine data
Moderna’s mRNA cancer vaccine trial results drive a 150% jump in its shares, lifting the S&P 500 and Swiss pharma stocks. US net interest payments hit a record 3.3% of GDP.
US stocks rise as Moderna surges; US net interest costs hit record high
Moderna’s 118% rally lifts biotech and Swiss pharma; Dow, S&P 500 and Nasdaq 100 advance. US net interest payments climb to 3.3% of GDP, highest on record.
Global stocks slip as yields surge; Swiss market edges up on pharma gains
Nasdaq leads losses as U.S. 30-year yields hit 19-year high. SMI ekes out gains on Roche, Novartis gains; ABB falls. Brent crude near $91, gold dips.
Swiss stocks rise as Roche, Novartis offset losses; Nasdaq falls sharply
SMI gains 0.13% with healthcare giants leading gains, while U.S. tech selloff drags Nasdaq down 1.49%. ABB and cyclicals decline as bond yields climb to multi-year highs.
Swiss stocks slip as global markets waver; Roche, Novartis advance
Swiss Market Index fell 0.13% as U.S. futures declined on rising bond yields and Middle East tensions. Roche and Novartis led Swiss gains, while cyclicals like ABB lagged. U.S. tech and AI-linked stocks retreated.
Swiss stocks slip as U.S. futures fall; Roche, Novartis rise; ABB leads declines
Swiss Market Index dips 0.13% as global equities drift lower on rising yields and Middle East tensions. Roche and Novartis gain, while cyclical stocks like ABB and construction firms retreat.
Swiss drugmakers limit reimbursement requests amid U.S. pricing pressures
Pharmaceutical firms in Switzerland are reducing applications for state reimbursement as U.S. drug pricing policies raise cost concerns.